Actelion Pharmaceuticals has launched an increased strength formulation of Ventavis (iloprost inhalation solution), an inhaled prostacyclin analogue, for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with New York Heart Association (NYHA) Class III or IV symptoms. The new 20mcg/mL increased strength formulation delivers the same dose as Ventavis 10mcg/mL in half the volume, which is expected to reduce inhalation time and support patient compliance.

Ventavis 20mcg/mL is available immediately for pre-order, and fulfillment of initial prescriptions by specialty pharmacies is anticipated beginning the week of September 14, 2009.

For more information call (877) 4VENTAVIS or visit